Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.
Fleseriu M, Pivonello R, Young J, Hamrahian AH, Molitch ME, Shimizu C, Tanaka T, Shimatsu A, White T, Hilliard A, Tian C, Sauter N, Biller BM, Bertagna X.
Fleseriu M, et al.
Pituitary. 2016 Apr;19(2):138-48. doi: 10.1007/s11102-015-0692-z.
Pituitary. 2016.
PMID: 26542280
Free PMC article.
Clinical Trial.